Oculis Holding AG (OCS) | Stock Overview & Key Data
Oculis Holding AG Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $23.08 on January 13, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Oculis Holding AG OCS | 1.00B Small-cap | -1.69% | -6.43% | 25.95% | -0.32% | 10.10% | 64.67% | 91.22% | 93.40% |
| Vertex VRTX | 114.06B Large-cap | 3.14% | 4.53% | -1.27% | 13.16% | 14.93% | -6.00% | 56.88% | 55.98% |
| Regeneron REGN | 55.27B Large-cap | 2.40% | 5.82% | -1.63% | -25.33% | -23.41% | -51.08% | -11.43% | -16.45% |
| Vera Therapeutics VERA | 1.38B Small-cap | 0.00% | 3.65% | 21.95% | -45.48% | -45.50% | -37.27% | 44.01% | 99.74% |
| Immunocore Holdings IMCR | 1.56B Small-cap | 1.34% | -7.73% | 35.67% | 10.09% | 11.60% | -17.97% | -25.06% | -24.98% |
| Agios AGIO | 1.93B Small-cap | 5.56% | 7.78% | 47.90% | 1.06% | 13.94% | -23.26% | 57.82% | -34.32% |
Ownership & Short Interest
Oculis Holding AG Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Oculis Holding AG would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
-
In the last 52 weeks, Oculis Holding AG reached a high of $23.08 (on January 13, 2025) and a low of $10.79 (on August 22, 2024).
-
Curious about Oculis Holding AG's size and valuation? Its market capitalization stands at 1.00B. When it comes to valuation, the P/E ratio (trailing twelve months) is 63.63, and the forward P/E (looking ahead) is -8.76.
-
As for dividends, Oculis Holding AG isn't currently offering a significant yield, or that specific data isn't available right now.
-
When looking at Oculis Holding AG, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX114.06B Healthcare Biotechnology -6.00% 56.88% Regeneron
REGN55.27B Healthcare Biotechnology -51.08% -11.43% Vera Therapeutics
VERA1.38B Healthcare Biotechnology -37.27% 44.01% Immunocore Holdings
IMCR1.56B Healthcare Biotechnology -17.97% -25.06% Agios
AGIO1.93B Healthcare Biotechnology -23.26% 57.82% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
-
To get a sense of Oculis Holding AG's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -85.16%, the Debt to Equity ratio from the most recent quarter is 0.68, and its Gross Profit Margin stands at N/A.
-
Looking at Oculis Holding AG's growth, its revenue over the trailing twelve months (TTM) was $916K. Compared to the same quarter last year (YoY), quarterly revenue grew by 28.40%, and quarterly earnings saw a YoY growth of N/A.
-
Wondering who owns Oculis Holding AG stock? Company insiders (like executives and directors) hold about 6.35% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 30.98%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.